Jiangsu Key Laboratory of Molecular Imaging and Functional Imaging, Department of Radiology, Zhong-Da Hospital, Medical School of Southeast University, Nanjing, China.
PLoS One. 2012;7(4):e34644. doi: 10.1371/journal.pone.0034644. Epub 2012 Apr 10.
Microbubbles (MBs) can serve as an ultrasound contrast agent, and has the potential for magnetic resonance imaging (MRI). Due to the relatively low effect of MBs on MRI, it is necessary to develop new MBs that are more suitable for MRI. In this study, we evaluate the properties of SonoVue® and custom-made Fe(3)O(4)-nanoparticle-embedded microbubbles (Fe(3)O(4)-MBs) in terms of contrast agents for ultrsonography (US) and MRI.
METHODOLOGY/PRINCIPAL FINDINGS: A total of 20 HepG2 subcutaneous-tumor-bearing nude mice were randomly assigned to 2 groups (i.e., n = 10 mice each group), one for US test and the other for MRI test. Within each group, two tests were performed for each mouse. The contrast agent for the first test is SonoVue®, and the second is Fe(3)O(4)-MBs. US was performed using a Technos(MPX) US system (Esaote, Italy) with a contrast-tuned imaging (CnTI™) mode. MRI was performed using a 7.0T Micro-MRI (PharmaScan, Bruker Biospin GmbH, Germany) with an EPI-T(2)* sequence. The data of signal-to-noise ratio (SNR) from the region-of-interest of each US and MR image was calculated by ImageJ (National Institute of Health, USA). In group 1, enhancement of SonoVue® was significantly higher than Fe(3)O(4)-MBs on US (P<0.001). In group 2, negative enhancement of Fe(3)O(4)-MBs was significantly higher than SonoVue® on MRI (P<0.001). The time to peak showed no significant differences between US and MRI, both of which used the same MBs (P>0.05). The SNR analysis of the enhancement process reveals a strong negative correlation in both cases (i.e., SonoVue® r = -0.733, Fe(3)O(4)-MBs r = -0.903, with P<0.05).
It might be important to change the Fe(3)O(4)-MBs' shell structure and/or the imagining strategy of US to improve the imaging quality of Fe(3)O(4)-MBs on US. As an intriguing prospect that can be detected by US and MRI, MBs are worthy of further study.
微泡(MBs)可用作超声造影剂,并具有磁共振成像(MRI)的潜力。由于 MBs 对 MRI 的影响相对较低,因此有必要开发更适合 MRI 的新型 MBs。在这项研究中,我们评估了 SonoVue®和定制的 Fe(3)O(4)-纳米颗粒嵌入微泡(Fe(3)O(4)-MBs)作为超声(US)和 MRI 造影剂的特性。
方法/主要发现:总共 20 只 HepG2 皮下肿瘤荷瘤裸鼠被随机分为 2 组(即每组 n = 10 只小鼠),一组进行 US 测试,另一组进行 MRI 测试。每组内,每只小鼠进行两次测试。第一次测试的造影剂是 SonoVue®,第二次是 Fe(3)O(4)-MBs。US 采用 Technos(MPX)US 系统(Esaote,意大利)和对比调谐成像(CnTI™)模式进行。MRI 采用 7.0T Micro-MRI(PharmaScan,Bruker Biospin GmbH,德国)和 EPI-T(2)*序列进行。通过 ImageJ(美国国立卫生研究院)计算每个 US 和 MR 图像的感兴趣区域的信噪比(SNR)数据。在第 1 组中,SonoVue®的增强明显高于 US 上的 Fe(3)O(4)-MBs(P<0.001)。在第 2 组中,MRI 上 Fe(3)O(4)-MBs 的负增强明显高于 SonoVue®(P<0.001)。US 和 MRI 使用相同的 MBs,因此峰值时间没有差异(P>0.05)。增强过程的 SNR 分析表明,两种情况下均存在强负相关(即 SonoVue®r = -0.733,Fe(3)O(4)-MBs r = -0.903,P<0.05)。
改变 Fe(3)O(4)-MBs 的壳结构和/或 US 的成像策略可能很重要,以提高 US 上 Fe(3)O(4)-MBs 的成像质量。作为一种可以通过 US 和 MRI 检测到的有趣前景,MBs 值得进一步研究。